188 related articles for article (PubMed ID: 10385711)
41. Thyrotropin receptor gene alterations in thyroid hyperfunctioning adenomas.
Russo D; Arturi F; Suarez HG; Schlumberger M; Du Villard JA; Crocetti U; Filetti S
J Clin Endocrinol Metab; 1996 Apr; 81(4):1548-51. PubMed ID: 8636365
[TBL] [Abstract][Full Text] [Related]
42. Lack of in vitro constitutive activity for four previously reported TSH receptor mutations identified in patients with nonautoimmune hyperthyroidism and hot thyroid carcinomas.
Jaeschke H; Mueller S; Eszlinger M; Paschke R
Clin Endocrinol (Oxf); 2010 Dec; 73(6):815-20. PubMed ID: 20846293
[TBL] [Abstract][Full Text] [Related]
43. TSH-activated signaling pathways in thyroid tumorigenesis.
Rivas M; Santisteban P
Mol Cell Endocrinol; 2003 Dec; 213(1):31-45. PubMed ID: 15062572
[TBL] [Abstract][Full Text] [Related]
44. The thyrotropin receptor in thyroid diseases.
Paschke R; Ludgate M
N Engl J Med; 1997 Dec; 337(23):1675-81. PubMed ID: 9385128
[No Abstract] [Full Text] [Related]
45. Contrasting effects of activating mutations of GalphaS and the thyrotropin receptor on proliferation and differentiation of thyroid follicular cells.
Ludgate M; Gire V; Crisp M; Ajjan R; Weetman A; Ivan M; Wynford-Thomas D
Oncogene; 1999 Aug; 18(34):4798-807. PubMed ID: 10490813
[TBL] [Abstract][Full Text] [Related]
46. G protein and thyrotropin receptor mutations in thyroid neoplasia.
Esapa C; Foster S; Johnson S; Jameson JL; Kendall-Taylor P; Harris PE
J Clin Endocrinol Metab; 1997 Feb; 82(2):493-6. PubMed ID: 9024242
[TBL] [Abstract][Full Text] [Related]
47. Cysteine 390 mutation of the TSH receptor modulates its ectodomain as an inverse agonist on the serpentine domain with decrease in basal constitutive activity.
Ho SC; Goh SS; Su Q; Khoo DH
Mol Cell Endocrinol; 2005 Dec; 245(1-2):158-68. PubMed ID: 16364538
[TBL] [Abstract][Full Text] [Related]
48. [Point mutations of the thyrotropin receptor gene in autonomously functioning thyroid gland nodules: correlation with clinical findings and morphology].
Lax SF; Semlitsch G; Schauer S; Zatloukal K; Langsteger W; Eber O; Höfler G
Verh Dtsch Ges Pathol; 1997; 81():145-50. PubMed ID: 9474865
[TBL] [Abstract][Full Text] [Related]
49. [TSH receptors in autonomous thyroid adenoma].
Mueller-Gaertner HW
Acta Med Austriaca; 1990; 17 Suppl 1():12-5. PubMed ID: 2202176
[No Abstract] [Full Text] [Related]
50. Primary culture of cells from hyperfunctioning thyroid adenoma with an activating mutation of G alphas.
Kamiya Y; Murakami M; Yanagita Y; Koitabashi H; Nagamachi Y; Hosoi Y; Ogiwara T; Mizuma H; Iriuchijima T; Mori M
Mol Cell Endocrinol; 1998 Mar; 138(1-2):137-42. PubMed ID: 9685222
[TBL] [Abstract][Full Text] [Related]
51. Congenital hyperthyroidism caused by a solitary toxic adenoma harboring a novel somatic mutation (serine281-->isoleucine) in the extracellular domain of the thyrotropin receptor.
Kopp P; Muirhead S; Jourdain N; Gu WX; Jameson JL; Rodd C
J Clin Invest; 1997 Sep; 100(6):1634-9. PubMed ID: 9294132
[TBL] [Abstract][Full Text] [Related]
52. TSH receptor and Gs-alpha gene mutations in the pathogenesis of toxic thyroid adenomas--a note of caution.
Derwahl M
J Clin Endocrinol Metab; 1996 Aug; 81(8):2783-5. PubMed ID: 8768829
[TBL] [Abstract][Full Text] [Related]
53. Gs alpha mutations in hyperfunctioning thyroid adenomas.
Murakami M; Kamiya Y; Yanagita Y; Mori M
Arch Med Res; 1999; 30(6):514-21. PubMed ID: 10714366
[TBL] [Abstract][Full Text] [Related]
54. New pathophysiological mechanisms for hyperthyroidism.
Vassart G
Horm Res; 1997; 48 Suppl 4():47-50. PubMed ID: 9350447
[TBL] [Abstract][Full Text] [Related]
55. The 3',5'-cyclic adenosine monophosphate response element binding protein (CREB) is functionally reduced in human toxic thyroid adenomas.
Brunetti A; Chiefari E; Filetti S; Russo D
Endocrinology; 2000 Feb; 141(2):722-30. PubMed ID: 10650954
[TBL] [Abstract][Full Text] [Related]
56. Molecular pathogenesis of thyroid nodules and cancer.
Moretti F; Nanni S; Pontecorvi A
Baillieres Best Pract Res Clin Endocrinol Metab; 2000 Dec; 14(4):517-39. PubMed ID: 11289733
[TBL] [Abstract][Full Text] [Related]
57. Biological activity of activating thyrotrophin receptor mutants: modulation by iodide.
Al-Khafaji F; Wiltshire M; Fuhrer D; Mazziotti G; Lewis MD; Smith PJ; Ludgate M
J Mol Endocrinol; 2005 Feb; 34(1):209-20. PubMed ID: 15691889
[TBL] [Abstract][Full Text] [Related]
58. TSH induces co-localization of TSH receptor and Na/K-ATPase in human erythrocytes.
Balzan S; Del Carratore R; Nicolini G; Forini F; Lubrano V; Simili M; Benedetti PA; Iervasi G
Cell Biochem Funct; 2009 Jul; 27(5):259-63. PubMed ID: 19466745
[TBL] [Abstract][Full Text] [Related]
59. Search for NTRK1 proto-oncogene rearrangements in human thyroid tumours originated after therapeutic radiation.
Bounacer A; Schlumberger M; Wicker R; Du-Villard JA; Caillou B; Sarasin A; Suárez HG
Br J Cancer; 2000 Jan; 82(2):308-14. PubMed ID: 10646882
[TBL] [Abstract][Full Text] [Related]
60. Molecular biology of thyroid neoplasms.
Satta MA; Nanni S; Della Casa S; Pontecorvi A
Rays; 2000; 25(2):151-61. PubMed ID: 11370534
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
